Company news

Actinogen Medical Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ACW XanaCIDD depression trial results expected early August

July 1, 2024

Positive Xanamem biomarker trial published in Jnl Alz Dis

June 26, 2024

ACW Oversubscribed $3.9 million entitlement offer completed

June 4, 2024

Actinogen entitlement offer closed and oversubscribed

May 29, 2024

Prospectus - Non-renounceable Entitlement Offer

May 6, 2024

Actinogen announces capital raising of up to $8.9 million

May 3, 2024

ACW March 2024 quarterly activity report & Appendix 4C

April 30, 2024

ACW completes cognition & depression phase 2 trial enrolment

April 21, 2024

First patient treated in ACW XanaMIA ph 2b Alzheimers trial

April 14, 2024

Actinogen HY2024 financial results two key phase 2 trial

February 25, 2024

Actinogen HY2024 financial report and Appendix 4D

February 25, 2024

Response to ASX Aware Query

February 19, 2024

Actinogen awarded UK Innovation Passport for Xanamem

February 15, 2024

ACW December 2023 quarterly activity report & Appendix 4C

January 29, 2024

Actinogen receives $4.8 million R&D tax incentive rebate

November 28, 2023

Actinogen September quarterly activity report & Appendix 4C

October 15, 2023

Actinogen enhances XanaMIA Phase 2b Alzheimers trial

September 26, 2023

Actinogen closes successful $10 million rights issue offer

September 7, 2023

Actinogen FY2023 results, following the science

August 30, 2023

ACW Appendix 4E and 2023 Annual Report

August 30, 2023

ACW secures further $0.5m rights issue shortfall commitment

August 29, 2023

ACW secures shortfall commitments of $4.56m for rights issue

August 14, 2023

Entitlement Offer Prospectus

August 7, 2023

Actinogen announces $10 million rights offer

August 1, 2023

Quarterly Activity Report & Appendix 4C

July 31, 2023

ACW AD trial amendment and Clinical Science Forum slides

May 23, 2023

Appendix 4D & Half-Year Financial Statements

February 22, 2023

FDA agrees to six-month Phase 2b Alzheimers Disease Trial

December 22, 2022

First patient treated in XanaCIDD Phase 2 Depression Trial

December 8, 2022

R&D tax incentive rebate received

October 20, 2022

ACW clinical biomarker study webcast presentation

October 9, 2022

ACW announces positive Alzheimers Disease clinical results

October 9, 2022

Actinogen FY22 Results - Accelerating Clinical Development

August 25, 2022

ACW Appendix 4E and 2022 Annual Report

August 25, 2022

ACW CEO presentation to Spark Plus Aust Equities Day

July 27, 2022

Application for quotation of securities - ACW

July 14, 2022

ACW announces Phase 2 trial designs for AD & MDD

June 13, 2022

Actinogen trial results & strategic update presentation

May 3, 2022

Actinogen prioritizes Alzheimers Disease & Depression

May 3, 2022

Quarterly Activity Report & Appendix 4C

April 27, 2022

ACW positive XanaMIA results webcast slide presentation

April 26, 2022

ACW announces positive XanaMIA results for Xanamem

April 26, 2022

Letter to Shareholders & Notice of General Meeting

March 1, 2022

Actinogen Medical: ACW CEO Presents at European Life Sciences Conference

February 28, 2022

Appendix 4D & Half-Year Financial Statements

February 23, 2022

Actinogen XanaMIA Part A trial results expected in April

February 10, 2022

Actinogen appoints XanaFX Phase 2 trial manager

February 8, 2022

Actinogen Medical: ACW CEO Presents at San Francisco Healthcare Conference

January 9, 2022

Capital Raising Completion

December 19, 2021

ACW Strategic Collaboration with Oxford Uni Researchers

December 6, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 88 decks. Every deck is listed under its year.